The deal priced below last closing price of $1.53. Jefferies, BofA and Cantor Fitzgerald are acting as joint book running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
- Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
- Inhibikase announces common stock and warrants offering, no amount given
- Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
- Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating